KAPIL COTEX LTD.

Skybiotech Healthcare Ltd has announced its 43rd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:00 AM at its registered office in Chh. Sambhaji Nagar (Aurangabad). The meeting will cover ordinary business, including the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Key agenda items also include the re-appointment of Mr. Prakashchandra Rathi as a director and the appointment of M/s. SPD & Associates as statutory auditors for a term of five years. The company has commenced dispatch of the AGM notice and Annual Report for FY2025-26 to its members.

Skybiotech Healthcare Ltd (formerly Kapil Cotex Limited) has submitted its Annual Report for the Financial Year 2025-2026, as per SEBI regulations. The report is available on the company's website. It details corporate information including the Board of Directors, Compliance Officer, CFO, Statutory Auditors, and Secretarial Auditor. The report also outlines the structure of the Annual Report, including the Board Report, Management Discussion and Analysis, Independent Auditor's Report, Financial Statements (Standalone and Consolidated), and Notes to Accounts. The filing also lists members of the Audit Committee, Stakeholder Relationship Committee, and Nomination and Remuneration Committee.

Skybiotech Healthcare Ltd announced its Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The Board of Directors approved these results and took on record the Limited Review Report from the Statutory Auditors, SPD & Associates. The board meeting was held on August 14, 2026, commencing at 5:00 PM and concluding at 8:45 PM.

Skybiotech Healthcare Ltd announced that its Board of Directors, in a meeting held on August 14, 2026, approved the Un-audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The Board also took on record the Limited Review Report issued by the Statutory Auditors. The meeting commenced at 5:00 PM and concluded at 8:45 PM on the same day.

Skybiotech Healthcare Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda item for this meeting is to consider and approve the company's un-audited financial results for the quarter ending June 30, 2026. A limited review report for these results will also be presented. The meeting will follow SEBI (LODR) Regulations, 2015, and may address other business matters with the chair's permission.

Skybiotech Healthcare Ltd has announced the closure of its trading window from July 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter ended June 30, 2026. This measure aligns with SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's internal code of conduct. All designated persons and their immediate relatives are prohibited from trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.

Skybiotech Healthcare Ltd has announced the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026. The Board of Directors approved the results in their meeting held on May 30, 2026, which commenced at 05:00 PM and concluded at 07:15 PM. The audit report and limited review report issued by the statutory auditors were also taken on record.

Skybiotech Healthcare Ltd has announced a meeting of its Board of Directors scheduled for May 30, 2026, to consider and approve the audited financial results and limited review report for the quarter and year ended March 31, 2026. The meeting will also address any other business with the chair's permission.

Skybiotech Healthcare Ltd has announced the closure of its trading window for considering and approving the audited financial results for the quarter and year ended on 31st March 2026. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's Code of Conduct for Prevention of Insider Trading and Code of Corporate Disclosure Practices. The trading window will remain closed from 1st April 2026 till the completion of 48 hours after the declaration of the audited financial results. All designated persons and their immediate relatives are advised not to enter into any transaction involving dealing or trading in the company's shares during this period.

Skybiotech Healthcare Ltd, formerly known as Kapil Cotex Limited, has submitted its un-audited financial results for the quarter ended on 31st December, 2025. The results were approved by the Board of Directors at their meeting held on Saturday, 14th February, 2026. The company is in the process of filing the financial results in the form of Integrated Financials within the stipulated time from the conclusion of the board meeting. The un-audited financial results (standalone and consolidated) for the quarter ended 31st December, 2025, have been reviewed by SPD AND ASSOCIATES CHARTERED ACCOUNTANTS.